PLRX
Healthcare BiotechnologyPliant Therapeutics, Inc.
$1.01
-0.02 -1.46% today Live
Price History
Not enough data
| Date | Price |
|---|---|
| Oct 6, 2026, live at 2:42 PM ET | 1.01 |
Key Stats
Market Cap
62.85M
Avg Volume
487,824
EPS
-$1.50
52W High
$1.95
52W Low
$1.01
Div. Yield
0.0%
Analyst Ratings
Sell0
Str Buy
0
Buy
3
Hold
0
Sell
1
Str Sell
Valuation
Forward P/E
-0.79
P/B Ratio
0.43
EV/EBITDA
0.73
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(50.3%)
Return on Assets
(23.3%)
Liquidity & Leverage
Current Ratio
9.90
Quick Ratio
9.64
Debt / Equity
0.20
Total Cash
158.10M
Total Debt
28.74M
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
pliantrx.com